|
Canada-0-TRANSFORMERS selskapets Kataloger
|
Firma Nyheter:
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Rizvi NA, Hellmann MD, Brahmer JR, et al Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer J Clin Oncol 2016;34:
- Nivolumab in the treatment of metastatic squamous non-small cell lung . . .
Progress in the treatment of patients with advanced stage squamous cell non-small cell lung cancer (NSCLC) has been limited An improvement in the understanding of tumor immunosurveillance has resulted in the development of the immune checkpoint inhibitors such as nivolumab
- Nivolumab Approved for Neoadjuvant and Adjuvant Treatment of Non-small . . .
The immunotherapy is now approved to treat certain lung cancers before and after surgery The U S Food and Drug Administration (FDA) has approved neoadjuvant nivolumab (Opdivo) with platinum-containing chemotherapy, followed by adjuvant nivolumab alone, for patients with non-small cell lung cancer (NSCLC) that can be surgically removed, is 4 cm or larger or has spread to the lymph nodes, and
- Non-Small Cell Lung Cancer (NSCLC) Treatment | OPDIVO® (nivolumab)
OPDIVO® (nivolumab) alone, or with YERVOY® (ipilimumab) can be used as an immunotherapy treatment option for adults with certain types of NSCLC Please see Indication and Important Safety Information Select your cancer type Non-small cell lung cancer (NSCLC) Advanced kidney cancer; Gastroesophageal cancer; Melanoma;
- Nivolumab and Chemotherapy for Early-Stage Lung Cancer
Non-small cell lung cancer, the most common form of lung cancer, has often already spread beyond the lungs when it is diagnosed, so research has largely focused on people with more advanced forms of the disease After a follow-up of at least 21 months, the patients who received nivolumab treatment lived on average 11 months longer without
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small . . .
Platinum-based doublet chemotherapy (PT-DC) is the current standard of care as first-line treatment of patients with advanced non–small-cell lung cancer (NSCLC) not driven by an epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement, with objective response rates (ORRs) of 15% to 32%, median progression-free survival (PFS) and overall survival (OS
- Nivolumab plus ipilimumab versus carboplatin-based doublet as first . . .
Lung cancer is the leading cause of cancer-related deaths in high-income countries and 85% of lung cancer cases are non-small-cell lung cancer (NSCLC), which is diagnosed at the metastatic stage in the majority of patients 1 Compared with chemotherapy, first-line immunotherapy-based regimens for the treatment of advanced NSCLC have
- Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab . . .
Nivolumab plus ipilimumab–based treatment regimens have shown long-term, durable efficacy benefits in patients with metastatic NSCLC Here we report clinical outcomes from a pooled analysis of patients with metastatic NSCLC and tumor programmed death-ligand 1 (PD-L1) lower than 1% treated with first-line nivolumab plus ipilimumab with or without two cycles of chemotherapy versus up to four
- Nivolumab treatment beyond progressive disease in advanced non-small . . .
Purpose: This study evaluated the efficacy and safety of nivolumab treatment beyond progressive disease (PD) in non-small cell lung cancer (NSCLC) Patients methods: Medical records of consecutive patients with advanced NSCLC who received nivolumab between December 2015 and December 2018 were reviewed Clinical outcomes of three groups of eligible patients who received nivolumab as a second
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Hellmann MD, Rizvi NA, Goldman JW, et al Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort
|
|